Rebirthel Co., Ltd. was founded in October, 2019.
Rebirthel aims to realize cell-based therapies against cancer or other immune-related diseases by using universal
T cells that are regenerated from pluripotent stem cells.
The strategy is based on methods developed by myself, Dr. Hiroshi Kawamoto (Kyoto University).
It has been shown to be effective to transfuse genetically engineered T cells that had originally been collected from patients.
However, such “autologous” settings have faced problems: costly, time-consuming, and dependent on the quality of the T cells themselves (from the patients).
To solve these problems, Rebirthel provides “off-the-shelf T cells” that can be universally used with any patients in an allogeneic setting.
Pluripotent stem cells such as iPS (induced pluripotent stem) cells or ES (embryonic stem) cells have the potential to produce various types of tissues/organs.
Rebirthel has already established a method by which potent killer T cells can be produced in vitro from iPS cells.
Using this method, Rebirthel is now developing a strategy where tumor antigen-specific T cells are mass-produced and transfused to patients as off-the-shelf T cells.
Certain types of T cells play the role of commander of immune cells, while other types serve as strong warriors.
Therefore, if we can produce different types of T cells - such as killer T cells, helper T cells, or regulatory T cells - covering a wide range of target antigens, we can provide therapeutic T cells targeting any kind of disease related to the immune system (e.g. cancer, infectious diseases, autoimmune diseases, allergies, etc.).
Rebirthel opens the way to a future when patients go to hospital to receive transfusion of T cells to treat their disease.
Kajii-cho, Kamigyo-ku, Kyoto 602-0841 Japan
Business Summary
Rebirthel operationalizes cell-based cancer immunotherapies developed by Professor Hiroshi Kawamoto (Institute for Frontier Life and Medical Sciences, Kyoto University).
Rebirthel will provide “universal” cytotoxic T lymphocytes regenerated from pluripotent stem cells, to be used as “off-the-shelf T cells” in cancer immunotherapy.
Company history
Rebirthel took over all projects and intellectual properties related to killer T cells.
･Regcell raised 620,000,000 JPY through a third-party allocation of new shares.
･Regcell raised 20,000,000 JPY through a third-party allocation of new shares.
Transferred cells will immediately be rejected if the HLA haplotype does not match to that of the recipient.
In the regenerative medicine field, induced pluripotent stem (iPS) cells stock projects have been promoted where iPS cells that have been produced from healthy donors carrying the same HLA haplotype in both mother and father-derived alleles.
The cells/tissues regenerated from such iPS cells are expected to be transplanted to recipients who have the same HLA haplotype of at least one allele without inducing a severe rejection reaction.
At present, the most frequent four iPS cell lines are available from the Center for iPS Cell Research and Application (Kyoto University), covering 35% of the Japanese population.
We transduce these iPS cells with exogenous TCR and regenerate killer T cells from these iPSCs. Such regenerated T cells will be given to the patients in a HLA homo-to-hetero transfusion setting.
When the HLA genes of iPS cells are deleted, cells/tissues regenerated from such HLA-null-iPS cells can be transplanted to any patient.
This strategy can be applied not only for iPS cells but also for ES cells.
OP9 cell line and its genetically modified derivatives
Rebirthel has succeeded all rights of the OP9 cells from Dr. Hiroaki Kodama (who originally established the OP9 cell line).
You are required to obtain a license from Rebirthel for commercial use of the OP9 cell line or its derivatives.
OP9 cells
Professor Hiroshi Kawamoto, a director of Rebirthel, appeared on the morning news program “Asa Chan” (TBS and its affiliated TV station) on July 22nd, 2021. In the slot titled “The front line of treat...
Professor Hiroshi Kawamoto’s laboratory, Kyoto University, is now making an exhibition of its research activity with a booth at Arab Health 2021, held in Dubai, UAE from June 21st to June 24th 2021. T...
Professor Hiroshi Kawamoto, a director of Rebirthel and the Vice Director of Institute for Frontier Life and Medical Sciences, Kyoto University, appeared on the TV program “Hodo Station” presented by ...
In the evening edition of Sankei Shimbun on May 15th, 2021, Professor Hiroshi Kawamoto’s research activity was introduced. The article entitled “Fast-growing university ventures” occupies a large spac...
Our office has moved to the following new address. Only the room number has been changed. There are no changes to our office telephone and fax number. Room 311, Creation Core Kyoto Mikuruma, 448...
Nikkei Biotechnology & Business is the leading news site of biotechnology in Japan. In its recent issue, Rebirthel is introduced. In the article, TCR-iPS cell method and DP method which are our pa...
Professor Hiroshi Kawamoto, an excecutive director of Rebirthel, is recently conducting the collaborative research to develop a new therapy for the novel coronavirus infection with Fujita Health Unive...
This video was taken when our executive director, Hiroshi Kawamoto (Professor, Institute for Frontier Life and Medical Sciences, Kyoto University) visited Fujita Health University at the start of the ...
In the morning edition of Kyoto Shimbun on October 15th, 2020 (Economy section, Page 15), the conclusion of the research collaboration agreement between Rebirthel and Fujita Health University was repo...
In the morning edition of Chunichi Shimbun on October 15th, 2020 (Page 3), the conclusion of the research collaboration agreement between Rebirthel and Fujita Health University was reported. The artic...
Privacy Policy
We will not use your personal information for any purpose other than contacting customers.
Please be sure to read our privacy policy.